The latest data point for Pfizer's ROS (Return on Sales) in Q3'25 stands at 19.97%, reflecting a solid positive performance amid recent quarterly fluctuations. This value indicates improved profitability margins compared to the preceding quarter, though it remains below the peak of 26.55% observed in Q3'24. Over the period from Q2'23 to Q3'25, Pfizer's ROS has exhibited high volatility, starting at 17.72% before plunging to a low of -29.22% in Q4'23, then recovering to positive territory with intermittent dips such as -0.07% in Q2'24 and -0.06% in Q4'24. Key trends include a general stabilization in positive percentages from Q1'24 onward, averaging around 15-20% in recent quarters, punctuated by a notable decline to -9.40% in Q4'25; no data is available for Q1'26. This pattern suggests operational challenges in certain periods, potentially tied to market or cost factors, with the area chart highlighting periods of growth recovery post-negative troughs.